Keyword: AstraZeneca

The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams.

Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.

The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on the map.

Ironwood will walk away from its deal for AstraZeneca’s billion-dollar gout treatment lesinurad, following poor market performance.

The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.

As it tussles over licensing checks and tries to gain a reprieve, AZ quietly announced that selumetinib has once again missed the mark in a cancer test.

4D will use its AAV vectors to create therapies that insert genes that code for therapeutic proteins into human cells.

AstraZeneca, Cambridge University and Lumicks formed a discovery hub focused on visualizing the molecules behind disease pathways and treatments.

A "multi-omic" analysis of more than 900 donor brains linked the amount of herpes virus in a person's brain to the presence of Alzheimer's markers.

Organ-chip developer Emulate gathered $36 million in VC financing and plans to include a wider range of diseases in its models for drug testing.